HIV-1 protease inhibitor-associated partial lipodystrophy: Clinicopathologic review of 14 cases

Journal of the American Academy of Dermatology

Volumn 42, Issue 2 I, 2000, Pages 193-198

  Pujol, Ramon M ^a   Domingo, Pere ^a   Xavier Matias Guiu, ^a   Francia, Esther ^a   Sanbeat, M Antonia ^a   Alomar, Agustí ^a   Vazquez, Guillermo ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDINAVIR; LAMIVUDINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; FEMALE; HISTOPATHOLOGY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; LIPODYSTROPHY; MALE; OBESITY; PRIORITY JOURNAL;

EID: 0033912769     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0190-9622(00)90125-7     Document Type: Article

References (23)

1. Ryan TJ, Curri SB. Hypertrophy and atrophy of fat. Clin Dermatol 1989;7:93-106.
2. Poley JR, Stickler GB. Progressive lipodystrophy: a clinical study of 50 patients. Am J Dis Child 1963;106:356-63.
3. Senior B, Gellis SS. The syndromes of total lipodystrophy and partial lipodystrophy. Pediatrics 1964;33:593-613.
4. Taylor WB, Honeycutt WM. Progressive lipodystrophy and lipotrophic diabetes. Arch Dermatol 1961;84:81-6.
5. Chantier S, Buzzanga JB, Paquin F. Partial lipodystrophy associated with a type 3 form of membranoproliferative glomerulonephritis. J Am Acad Dermatol 1987;16:201-5.
6. Bird WG, Wilkinson JD. The clinical significance of partial lipoatrophy and C3 hypocomplementemia. Clin Exp Dermatol 1996; 21:131-4.
7. Font J, Herrero C, Bosch X, Cervera R, Ingelmo M, Mascaró JM. Systemic lupus erythematosus in a patient with partial lipodystrophy. J Am Acad Dermatol 1990;22:337-40.
8. Miller KD, Jones E, Yanovski JA, Shankar R, Feuersein I, Faloon J. Visceral abdominal-fat accumulation associated with the use of indinavir. Lancet 1998;351:871-5.
9. Deeks SG, Smith M, Holodny M, Kahn JO. HIV-1 protease inhibitors: a review for clinicians. JAMA 1997;277:145-53.
10. Dubé MP, Sattler FR. Metabolic complications of antiretroviral therapies. AIDS Clin Care 1998;10:41-4.
11. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia, and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998,12:F51-8.
12. Viraben R, Aquilina C. Indinavir-associated lipodystrophy. AIDS 1998;12:F37-9.
13. Herry I, Bernard L, de Truchis P, Perrone C. Hypertrophy of the breast in a patient treated with indinavir. Clin Infect Dis 1997;25:937-8.
14. Lo JC, Mulligna K, Tai VW, Algren H, Schambelan M. "Buffalo hump" in men with HIV infection. Lancet 1998;351:867-70.
15. Hengel RL, Watts NB, Lennox JL. Benign symmetric lipomatosis associated with protease inhibitors [letter]. Lancet 1997;350: 1596.
16. Roth VR, Kravick S, Angel JB. Development of cervical fat pads following therapy with human immunodeficiency virus type I protease inhibitors. Clin Infect Dis 1998;27:65-7.
17. Miller KK, Daly PA, Sentochnick D, Doweiko J, Samore M, Basgoz NO, et al. Pseudo-Cushing's syndrome in human immunodeficiency virus-infected patients. Clin Infect Dis 1998;27:68-72.
18. Peters MS, Winkelmann RK. Localized lipoatrophy (atrophic connective tissue panniculitis). Arch Dermatol 1980;116:1363-8.
19. Peters MS, Winkelmann RK. The histopathology of localized lipoatrophy. Br J Dermatol 1986;114:27-36.
20. Zalla MJ, Winkelmann RK, Gluck OS. Involutional lipoatrophy: macrophage-related involution of fat lobules. Dermatology 1995;191:149-53.
21. Dahl PR, Zalla MJ, Winkelmann RK. Localized involutional lipoatrophy: a clinicopathological review of 16 patients. J Am Acad Dermatol 1996;35:523-8.
22. Hirsch MS, Klibanski A. Editorial response: What price progress? Pseudo-Cushing's syndrome associated with antiretroviral therapy in patients with human immunodeficiency virus infection. Clin Infect Dis 1998;27:73-5.
23. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998;351:1881-3.